AdultPediatricDosage Forms & Strengths injection 10mcg Haemophilus b, 25mcg tetanus toxoid/0.5mL (ActHIB, Hiberix) 7.5mcg Haemophilus b PRP, 125mcg Neisseria meningitidis OMPC/0.5 mL (PedVaxHib) H. influenzae Type B Immunization Not indicated for routine immunization in otherwise healthy adults For more information, see the CDC vaccine guidelines at http://www.cdc.gov/vaccines/schedules/hcp/index.html Asplenia Indicated for adults with functional or anatomic asplenia (including sickle cell disease) or are undergoing elective splenectomy One dose of HIB vaccine should be administered if HIB vaccine not previously received HIB vaccination should be given ≥14 days before splenectomy Complement deficiency Indicated for adults with persistent complement component deficiencies One dose of HIB vaccine should be administered if HIB vaccine not previously received Post-HSCT Recipients Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history At least 4 weeks should separate doses Dosing Considerations Not recommended for adults with HIV infection since their risk for HIB infection is low, unless another risk factor is present (ie, asplenia, complement deficiency, HSCT recipient)Dosage Forms & Strengths injection 10mcg Haemophilus b, 25mcg tetanus toxoid/0.5mL (ActHIB, Hiberix) 7.5mcg Haemophilus b PRP, 125mcg Neisseria meningitidis OMPC/0.5 mL (PedVaxHib) H. influenzae Type B Immunization IM injection indicated for routine immunization in children aged 2 months to 15 months and up to 5 years for catch up vaccination Primary series (6 weeks to 12 months): 2 or 3 doses Booster: 3rd or 4th dose between 12-15 months PRP-OMP Monovalent vaccine; polyribosylribotol phosphate (PRP) conjugated to outer membrane protein (OMP) complex from Neisseria meningitidis PEDvaxHIB: 2 and 4 months (primary series); 12-15 months (booster) PRP-T Monovalent vaccines; polyribosylribotol phosphate (PRP) conjugated to tetanus toxoid (T) ActHIB, Hiberix: 0.5 mL IM as 4-dose series at 2, 4, and 6 months (primary series) and between 12-15 months (booster) Combination vaccines PRP-OMP-HepB (Comvax): 2 and 4 months (primary series); 12-15 months (booster) DTap-IPV/PRP-T (Pentacel): 2, 4, and 6 months (primary series); 12-15 months (booster) MenCY-PRP-T (MenHibRix): 2, 4, and 6 months (primary series); 12-15 months (booster) Considered fully immunized if At least 1 dose after age 14 months, or 2 doses between 12-14 months old, or >2 doses during first year of life followed by booster when older than 1 yr Immunosuppressed individuals Consider administering in patients 5 years or older if not already vaccinated and are immunosuppressed (eg, sickle cell disease, leukemia, HIV or anatomic/functional asplenia) Dosing Considerations PRP-T: Polyribosylribotol phosphate conjugated to tetanus toxoid OMP: Outer membrane protein complex from Neisseria meningitidis Minimum age for vaccination is 6 weeks old for PRP-T (ActHIB), DTaP-IPV/Hib (Pentacel), and Hib-MenCY (MenHibrix), or PRP-OMP (PedvaxHIB, Comvax) Minimum age for vaccination is 12 months old for PRP-T (Hiberix) ActHIB: Reconstituted with 0.4% NaCl diluent is indicated for active immunization of children aged 2 months through 5 years for prevention of invasive disease caused by Haemophilus influenzae type b TriHIBit: ActHIB reconstituted with Tripedia (DTP) vaccine creates TriHIBit vaccine; it is indicated for the active immunization of children aged 15 through 18 months for prevention of invasive disease caused by Haemophilus influenzae type b and diphtheria, tetanus and pertussisInteraction CheckerEnter a drug name and haemophilus influenzae type b vaccineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (4)elivaldogene autotemcelelivaldogene autotemcel, haemophilus influenzae type b vaccine. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .ofatumumab SCofatumumab SC decreases effects of haemophilus influenzae type b vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible.siponimodsiponimod decreases effects of haemophilus influenzae type b vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk.teplizumabteplizumab decreases effects of haemophilus influenzae type b vaccine by Other (see comment). Avoid or Use Alternate Drug. Comment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment.Monitor Closely (56)adalimumabadalimumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.anakinraanakinra decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.antithymocyte globulin equineantithymocyte globulin equine decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.antithymocyte globulin rabbitantithymocyte globulin rabbit decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.azathioprineazathioprine decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.basiliximabbasiliximab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.brodalumabbrodalumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.budesonidebudesonide decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.canakinumabcanakinumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.certolizumab pegolcertolizumab pegol decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.chloroquinechloroquine decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.cortisonecortisone decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.cyclosporinecyclosporine decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). .deflazacortdeflazacort decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.delandistrogene moxeparvovecdelandistrogene moxeparvovec, haemophilus influenzae type b vaccine. Other (see comment). Use Caution/Monitor. Comment: Consider patient vaccination status before initiating corticosteroid regimen required before delandistrogene moxeparvovec administration. If possible, ensure patients are current with all immunizations according to immunization guidelines. Complete vaccinations at least 4 weeks before starting corticosteroid regimen. High-dose or long-term corticosteroids may decrease immungenicity of vaccines.dengue vaccinedengue vaccine, haemophilus influenzae type b vaccine. unspecified interaction mechanism. Use Caution/Monitor. Data are not available to establish safety and immunogenicity of coadministration of dengue vaccine with recommended adolescent vaccines.dexamethasonedexamethasone decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.etanerceptetanercept decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.everolimuseverolimus decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.fludrocortisonefludrocortisone decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.glatiramerglatiramer decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.golimumabgolimumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.hydrocortisonehydrocortisone decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence